文献速递炎症性肠病

综述:鞘氨醇1磷酸/鞘氨醇1磷酸受体轴——炎症性肠病的独特治疗靶点

Review article: the sphingosine 1 phosphate/sphingosine 1 phosphate receptor axis - a unique therapeutic target in inflammatory bowel disease.
PubMed 文献 · Aliment Pharmacol Ther · 2021-12-21

本文为叙述性综述,经PubMed与ClinicalTrials.gov检索,概述鞘氨醇1磷酸受体(S1PR)生物学进展及S1P受体调节剂在慢性炎症性疾病尤其是炎症性肠病(IBD)中的临床前与临床研究。S1PR通过调控淋巴细胞迁移等多种细胞过程发挥作用;奥扎尼莫德已获美国食品药品监督管理局批准用于成人中重度活动性溃疡性结肠炎,多种S1PR调节剂正在溃疡性结肠炎和克罗恩病中开展临床研发。

要点

  • 奥扎尼莫德为高选择性S1PR1/5调节剂,已获批用于成人中重度活动性溃疡性结肠炎。
  • 多种S1PR调节剂正在溃疡性结肠炎和克罗恩病的临床研发项目中测试。
  • S1PR调节剂是治疗IBD的新型、有前景、安全且便利的策略。

核心结论

  • S1P受体调节剂构成治疗IBD的新型、有前景、安全且便利的策略。

研究设计与样本

  • 叙述性综述,检索PubMed与ClinicalTrials.gov。

主要发现

  • 通过S1PR,S1P调控增殖、迁移、存活和血管屏障完整性等多种细胞过程。
  • S1PR调节淋巴细胞运输的功能已广为人知,S1PR的新功能拓展了对S1PR生物学的认识。
  • 多种S1PR调节剂正在溃疡性结肠炎和克罗恩病中开展临床研发,在II期和III期研究中显示前景,奥扎尼莫德现已获批用于溃疡性结肠炎。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Ozanimod, a high selective sphingosine 1 phosphate (S1P) receptor (S1PR) 1/5 modulator was approved by the Food and Drug Administration for the treatment of adult patients with moderately to severely active ulcerative colitis. Additional S1PR modulators are being tested in clinical development programmes for both ulcerative colitis and Crohn's disease. AIM: To provide an overview of advances in understanding S1PRs biology and summarise preclinical and clinical investigations of S1P receptor modulators in chronic inflammatory disease with special emphasis on inflammatory bowel diseases (IBD). METHODS: We performed a narrative review using PubMed and ClinicalTrials.gov. RESULTS: Through S1PRs, S1P regulates multiple cellular processes, including proliferation, migration, survival, and vascular barrier integrity. The S1PRs function of regulating lymphocyte trafficking is well known, but new functions of S1PRs expand our knowledge of S1PRs biology. Several S1PR modulators are in clinical development for both ulcerative colitis and Crohn's disease and have shown promise in phase II and III studies with ozanimod now being approved for ulcerative colitis. CONCLUSIONS: S1P receptor modulators constitute a novel, promising, safe, and convenient strategy for the treatment of IBD.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Wang J, Goren I, Yang B, et al. Review article: the sphingosine 1 phosphate/sphingosine 1 phosphate receptor axis - a unique therapeutic target in inflammatory bowel disease. Aliment Pharmacol Ther. 2021. PMID: 34932238. doi:10.1111/apt.16741

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。